It is too early to say, but Cyltezo’s interchangeable status could boost its position on the market, says Jonathan Watanabe, PhD, professor of clinical pharmacy at University of California, Irvine. This depends on whether Cyltezo becomes a preferred agent at the formularies, he says.

Read the full article here.